Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids
A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose
Sponsor: GlaxoSmithKline
Listed as NCT00353873, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Almere Stad, Netherlands , Almería, Spain , Barcelona, Spain , Beek en Donk, Netherlands , Bialystok, Poland , Bruges, Belgium , Brussels, Belgium , Daugavpils, Latvia , Deurne, Netherlands and 48 more locations